Advertisement
Screener

CULLINAN THERAPEUTICS, INC. (CGEM) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

CULLINAN THERAPEUTICS, INC. Cash Flow Breakdown

Cash flow breakdown shows where CULLINAN THERAPEUTICS, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $175.75M went out.
  • Fiscal year ended 2025-12-31: from investing, $179.99M came in.
  • Fiscal year ended 2025-12-31: from financing, $1.09M came in.
  • Fiscal year ended 2025-12-31: change in cash, $5.33M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksNew shares soldNot split outChange in cash
2025-12-31-$175.75M$179.99M$0.00$1.09M*$5.33M
2024-12-31-$145.30M-$136.31M$262.65M$3.54M*-$15.43M
2023-12-31-$134.28M$35.81M$38.39M$2.36M*-$57.72M
2022-12-31-$126.66M$248.97M$0.00-$25.93M*$96.38M
2021-12-31-$43.43M-$333.77M$3.28M$265.50M*-$108.42M
2020-12-31-$29.77M-$5.42M-$6.57M$145.45M$1.26M*$104.95M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$38.22M*$40.68M*$1.10M*
2026-03-31-$46.05M$32.41M-$13.25M
2025-12-31-$38.11M*$22.39M*$0.00*$715.00K*
2025-09-30-$36.88M*$67.39M*$0.00*
2025-06-30-$57.61M*$53.40M*
2025-03-31-$43.16M$36.80M-$6.35M
2024-12-31-$36.63M*$15.96M*$0.00*$1.58M*
2024-09-30-$34.14M*$19.88M*$0.00*$1.32M*
2024-06-30-$36.29M*-$185.11M*$262.20M*
2024-03-31-$38.25M$12.96M$1.08M*-$24.21M
2023-12-31-$18.13M*$51.47M*$0.00*
2023-09-30-$34.14M*-$42.96M*$0.00*
2023-06-30-$31.01M*$12.11M*$38.42M*
2023-03-31-$51.00M$15.18M$1.79M*-$34.02M
2022-12-31-$24.98M*-$28.61M*$0.00*-$32.91M*
2022-09-30-$54.35M*-$57.98M*$0.00*$1.43M*
2022-06-30-$25.42M*$300.85M*-$1.59M*$3.60M*
2022-03-31-$21.91M$34.71M-$22.00K$1.59M$1.98M*$16.34M
2021-12-31-$15.17M*-$15.86M*$2.70M*
2021-09-30-$10.55M*-$25.59M*$579.00K*
2021-06-30-$16.20M*-$154.59M*$923.00K*
2021-03-31-$1.51M-$137.73M$264.58M*$125.34M
2020-12-31-$9.44M*$11.44M*-$6.36M*$131.20M*
2020-09-30-$9.07M*-$1.94M*$0.00*$0.00*$1.21M*
2020-06-30-$6.25M*$11.97M*$0.00*$0.00*
2020-03-31-$5.01M-$26.89M-$213.00K$14.25M-$17.87M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Replimune Group, Inc. (REPL)United States$1.186B-3.13
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10